DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)

Information source: Sirion Therapeutics, Inc.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Inflammation

Intervention: Difluprednate (Drug); Difluprednate (Drug); Placebo (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Sirion Therapeutics, Inc.

Official(s) and/or principal investigator(s):
Roger Vogel, MD, Study Chair, Affiliation: Sirion Therapeutics, Inc.

Summary

The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.

Clinical Details

Official title: A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo).

Eligibility

Minimum age: 2 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Unilateral ocular surgery in the day prior to study enrollment.

- Anterior chamber cell grade ≥ "2" on the day after surgery (Day 1).

- Aged 2 years or older on the day of consent.

- Negative urine pregnancy test on Day 1 for postmenarchal subjects; negative urine

pregnancy test for premenarchal subjects at the investigator's discretion.

- Provide signed written consent prior to entering the study or signed written consent

from parent or legal guardian if subject is a minor and signed assent from minor subject, if appropriate. Presurgical Exclusion Criteria:

- Systemic administration of any corticosteroid in the 2 weeks prior to study

enrollment.

- Periocular injection in the study eye of any corticosteroid solution within 4 weeks

prior to instillation of the study drug, or of any corticosteroid depot within 2 months prior to instillation of the study drug.

- Instillation of any topical ocular corticosteroid or NSAID within 24 hours prior to

instillation of the study drug or during the course of the study, with the exception of presurgical administration of a topical NSAID to prevent miosis.

- Any history of glaucoma or ocular hypertension in the study eye.

- History or presence of endogenous uveitis.

- Any current corneal abrasion or ulceration.

- Any confirmed or suspected active viral, bacterial, or fungal keratoconjunctival

disease.

- Allergy to similar drugs, such as other corticosteroids.

- History of steroid-related IOP increase.

- Scheduled surgery on the contralateral eye during the treatment period.

- Unwilling to discontinue use of contact lenses during the study period.

- Pregnancy or lactation.

- Participation in any study of an investigational topical or systemic new drug or

device within 30 days prior to screening, or at any time during the study.

- Prior participation in the study described in this protocol.

- Unable or unwilling to give signed informed consent prior to participation in any

study related procedures. Postsurgical Exclusion Criteria:

- Ocular hemorrhage which interferes with evaluation of postsurgery inflammation.

- Injection of gas into the vitreous body during surgery.

- Presence of IOP ≥24 mm Hg on Day 1 after surgery.

Locations and Contacts

Comprehensive Eye Care, Washington, Missouri 63090, United States
Additional Information


Last updated: May 12, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017